リボソーム二量体化の新機構を解明~リボソーム機能制御機構研究の新展開~

ad

2025-03-28 新潟大学

新潟大学の研究チームは、2025年3月27日に発表された研究成果において、新しい抗がん剤の候補となる化合物を特定しました。この化合物は、がん細胞の増殖を抑制する効果が確認されており、特に難治性のがん種に対して有望な結果が得られています。研究チームは、今後さらなる前臨床試験を進め、安全性と有効性の評価を行う予定です。この成果は、将来的ながん治療の選択肢を広げる可能性があり、医療分野における重要な一歩とされています。

<関連情報>

ユニークな 30S-30S 二量体化を促進する新規古細菌リボソーム二量体化因子 Novel archaeal ribosome dimerization factor facilitating unique 30S–30S dimerization

Ahmed H Hassan, Matyas Pinkas, Chiaki Yaeshima, Sonoko Ishino, Toshio Uchiumi, Kosuke Ito, Gabriel Demo
Nucleic Acids Research  Published:11 January 2025
DOI:https://doi.org/10.1093/nar/gkae1324

リボソーム二量体化の新機構を解明~リボソーム機能制御機構研究の新展開~
Graphical Abstract

Abstract

Protein synthesis (translation) consumes a substantial proportion of cellular resources, prompting specialized mechanisms to reduce translation under adverse conditions. Ribosome inactivation often involves ribosome-interacting proteins. In both bacteria and eukaryotes, various ribosome-interacting proteins facilitate ribosome dimerization or hibernation, and/or prevent ribosomal subunits from associating, enabling the organisms to adapt to stress. Despite extensive studies on bacteria and eukaryotes, understanding factor-mediated ribosome dimerization or anti-association in archaea remains elusive. Here, we present cryo-electron microscopy structures of an archaeal 30S dimer complexed with an archaeal ribosome dimerization factor (designated aRDF), from Pyrococcus furiosus, resolved at a resolution of 3.2 Å. The complex features two 30S subunits stabilized by aRDF homodimers in a unique head-to-body architecture, which differs from the disome architecture observed during hibernation in bacteria and eukaryotes. aRDF interacts directly with eS32 ribosomal protein, which is essential for subunit association. The binding mode of aRDF elucidates its anti-association properties, which prevent the assembly of archaeal 70S ribosomes.

有機化学・薬学
ad
ad
Follow
ad
タイトルとURLをコピーしました